CBD is phenomenally popular right now. It’s being used to treat pain, anxiety, epilepsy, psychosis, and even neurodegenerative diseases like Alzheimer’s and Parkinson’s. It’s been called a “wonder drug,” without irony, and it has essentially no known downsides. It is readily available and easy to take.
At the same time, it’s important to be aware that CBD can interact with some medications. Taking it at the same time as other drugs can affect CBD’s dosage and effects, and can even change how your body breaks it down.
This article is your guide to safely taking CBD alongside your other medications and supplements. First, it has a quick overview of how CBD interacts with other drugs in your body, and then it lists the most common drugs that interact with CBD, and which you should be careful about taking at the same time. If you want to skip ahead, you can find the list here.
The CYP450 Pathway
Once a drug enters your system, its molecules are circulated through your blood and interact with your cells and tissues, doing whatever it is they’re supposed to do. Painkillers reduce pain signals and can stop swelling, antidepressants interact with brain cells to change your brain chemistry, and so on.
Once they’ve done their work, your body needs to get rid of the drug molecules. Too much of any drug in your bloodstream is toxic, and can start to harm your body.
Your body uses all kinds of systems to get rid of drugs, and the most important of these are enzymes–chemicals that break down other chemicals. The largest set of enzymes are the cytochrome p-450 group (or CYP450), which are responsible for breaking down about 75% of the medications and recreational drugs that we take.
CBD and the CYP450 Pathway
CBD interacts with the CYP450 system in three ways. First, some of the enzymes in the system are responsible for breaking down CBD molecules, as they are for molecules of other drugs. That’s normal–nothing to worry about there.
Second, CBD can affect how CYP450 enzymes are produced by your liver, making it produce not enough of some enzymes or too much of others. This can stop your liver from processing some drugs, like the epilepsy medications clobazam and valproic acid.
Third, and most importantly, CBD can actually stop many of the CYP system’s enzymes from working properly. This is called “inhibition,” and it can cause problems if it prevents the enzymes from breaking down other drugs. Sometimes, the enzymes are responsible for activating other drugs instead, but the same problem comes up–if CBD stops the enzyme from working, then it doesn’t do its normal job, and the other drug won’t behave normally, which can have negative consequences.
For instance, there’s a group of antidepressants called selective-serotonin reuptake inhibitors, which include drugs like citalopram, norfluoxetine, and sertraline. Normally, an enzyme called CYP3A4 breaks down molecules of those drugs, making sure they don’t build up to unsafe levels that can damage cells or tissues. CBD inhibits CYP3A4, though, which means that taking CBD and sertraline at the same time could be dangerous. CYP3A4 wouldn’t break the sertraline down, and it would accumulate for far too long.
It’s worth noting that CBD isn’t the only thing that does this. The herbs St. John’s Wort and goldenseal can also stop CYP450 enzymes from working properly, as can grapefruit and starfruit juice, and even tobacco.
Drugs that Interact with CBD List
That brings us to our list. Remember, the general rule is that you need to be careful taking CBD at the same time as any drug or medication that gets processed by CYP450 enzymes. If you’re thinking about doing so, be sure to check with your doctor first.
Here are the most common of those drugs and medications. They include many painkillers, anti-inflammatories, antipsychotics, antidepressants, anticonvulsants, statins, opioids, and other groups.
- Alprazolam (Xanax)
- Amitriptyline (Elavil)
- Amlodipine (Norvasc)
- Carbamacepin (Tegretol, Equetro)
- Carisoprodol (Soma)
- Celecoxib (Celebrex)
- Chlordiazepoxide (Librium)
- Chlormethiazole (Heminevrin)
- Chlorzoxazone (Lorzone)
- Clarithromycin (Biaxin)
- Clobazam (Onfi)
- Clorazepate (Tranxene-SD)
- Clozapine (Clozaril, FazaClo)
- Codeine (Tylenol)
- Cyclosporine (Sandimmune)
- Desipramine (Norpramin)
- Dexamethasone (Decadron)
- Diazepam (Diastat, Valium)
- Diclofenac (Cataflam, Voltaren)
- Disulfiram (Antabuse)
- Erlotinib (Tarceva)
- Eslicarbazepine acetate (Eslicarbazepine)
- Estazolam (ProSom)
- Fentanyl (Duragesic, Sublimaze)
- Fexofenadine (Allegra)
- Flecainide (Tambocor)
- Flurazepam (Dalmane)
- Flutamide (Eulexin)
- Glipizide (Glucotrol)
- Halazepam (Pazipam)
- Haloperidol (Haldol)
- Halothane (Fluothane)
- Ibuprofen (Motrin)
- Imipramine (Tofranil)
- Itraconazole (Sporanox, Onmel)
- Ketamine (Ketalar)
- Ketoconazole (Nizoral, Extina)
- Ketoconazole (Nizoral)
- Klonipin (Clonazepam)
- Lansoprazole (Prevacid)
- Lorazepam (Ativan)
- Losartan (Cozaar)
- Lovastatin (Mevacor)
- Meloxicam (Mobic)
- Methoxyflurane (Penthrox)
- Metoprolol (Lopressor, Toprol XL)
- Nelfinavir (Viracept)
- Nifedipine (Adalat CC, Procardia XL)
- Omeprazole (Prilosec, Omesec)
- Ondansetron (Zofran)
- Orphenadrine (Norflex)
- Oxaliplatin (Eloxatin)
- Oxezepam (Serax)
- Pantoprazole (Protonix)
- Paroxetine (Paxil)
- Pentobarbital (Nembutal)
- Phenobarbital (Luminal, Solfoton)
- Phenytoin (Dilantin)
- Piroxicam (Feldene)
- Progesterone (Endometrin, Prometrium)
- Propofol (Diprivan)
- Propranolol (Inderal)
- Quazepam (Doral)
- Rifampicin (Rifadin)
- Risperidone (Risperdal)
- Ritonavir (Norvir)
- Rufinamide (Banzel)
- Secobarbital (Seconal)
- Temazepam (Restoril)
- Theophylline (Theo-Dur, Theo-24, Theocron, Elixophylline)
- Thiopental (Pentothal)
- Topiramate (Topamax)
- Tramadol (Ultram)
- Triazolam (Halcion)
- Valproic acid (Depacon)
- Venlafaxine (Effexor)
- Verapamil (Calan, Isoptin, others)
- Warfarin (Coumadin)
- Zonisamide (Zonegran)
Ball, S. E., Ahern, D., Scatina, J., & Kao, J. (1997). Venlafaxine: in vitro inhibition of CYP2D6 dependent imipramine and desipramine metabolism; comparative studies with selected SSRIs, and effects on human hepatic CYP3A4, CYP2C9 and CYP1A2. British Journal of Clinical Pharmacology, 43(6), 619-626.
Bergamaschi, M. M., Queiroz, R. H. C., Chagas, M. H. N., De Oliveira, D. C. G., De Martinis, B. S., Kapczinski, F., Quevado, J., Roesler, R., SchrÃ¶der, N., Nardi, A. E., Martin-Santos, R., Hallak, J. E. C., Zuardi, A. W., & Crippa, J. A. S. (2011). Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naive social phobia patients. Neuropsychopharmacology, 36(6), 1219.
Boggs, D. L., Nguyen, J. D., Morgenson, D., Taffe, M. A., & Ranganathan, M. (2018). Clinical and preclinical evidence for functional interactions of cannabidiol and ? 9-tetrahydrocannabinol. Neuropsychopharmacology, 43(1), 142.
Bornheim, L. M., & Grillo, M. P. (1998). Characterization of cytochrome P450 3A inactivation by cannabidiol: possible involvement of cannabidiol-hydroxyquinone as a P450 inactivator. Chemical Research in Toxicology, 11(10), 1209-1216.
Chatterjee, P., & Franklin, M. R. (2003). Human cytochrome p450 inhibition and metabolic-intermediate complex formation by goldenseal extract and its methylenedioxyphenyl components. Drug Metabolism and Disposition, 31(11), 1391-1397.
FASS VÃ¥rdpersonal. (2019). “Sativex.” Medication database. Retrieved from https://www.fass.se/LIF/product?userType=0&nplId=20101019000051#interaction
Haddad, A., Davis, M., & Lagman, R. (2007). The pharmacological importance of cytochrome CYP3A4 in the palliation of symptoms: review and recommendations for avoiding adverse drug interactions. Supportive Care in Cancer, 15(3), 251-257.
Hazekamp, A. (2018). The trouble with CBD oil. Medical Cannabis and Cannabinoids, 1(1), 65-72.
Hurd, Y. L. (2017). Cannabidiol: swinging the marijuana pendulum from ‘weed’ to medication to treat the opioid epidemic. Trends in Neurosciences, 40(3), 124-127.
Johnson, J. R., Burnell-Nugent, M., Lossignol, D., Ganae-Motan, E. D., Potts, R., & Fallon, M. T. (2010). Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC: CBD extract and THC extract in patients with intractable cancer-related pain. Journal of Pain and Symptom Management, 39(2), 167-179.
Kroon, L. A. (2007). Drug interactions with smoking. American Journal of Health-System Pharmacy, 64(18), 1917-1921.
Leweke, F. M., Piomelli, D., Pahlisch, F., Muhl, D., Gerth, C. W., Hoyer, C., KlosterkÃ¶tter, J., Hellmich, M., & Koethe, D. (2012). Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Translational Psychiatry, 2(3), e94.
Masubuchi, Y., & Kawaguchi, Y. (2013). Time?dependent inhibition of CYP3A4 by sertraline, a selective serotonin reuptake inhibitor. Biopharmaceutics & Drug Disposition, 34(8), 423-430.
Nadulski, T., Pragst, F., Weinberg, G., Roser, P., Schnelle, M., Fronk, E. M., & Stadelmann, A. M. (2005). Randomized, double-blind, placebo-controlled study about the effects of cannabidiol (CBD) on the pharmacokinetics of Delta9-tetrahydrocannabinol (THC) after oral application of THC verses standardized cannabis extract. Therapeutic Drug Monitoring, 27(6), 799-810.
Samer, C. F., Lorenzini, K. I., Rollason, V., Daali, Y., & Desmeules, J. A. (2013). Applications of CYP450 testing in the clinical setting. Molecular Diagnosis & Therapy, 17(3), 165-184.
United States National Library of Medicine. (2018). “Cannabidiol.” MedLine Plus. Retrieved from https://medlineplus.gov/druginfo/natural/1439.html
Williams, J. A., Hyland, R., Jones, B. C., Smith, D. A., Hurst, S., Goosen, T. C., Peterkin, V., & Koup, J. R., & Ball, S. E. (2004). Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metabolism and Disposition, 32(11), 1201-1208.
Zendulka, O., DovrtelovÃ¡, G., NoskovÃ¡, K., Turjap, M., SulcovÃ¡, A., Hanus, L., & Jurica, J. (2016). Cannabinoids and cytochrome P450 interactions. Current Drug Metabolism, 17(3), 206-226.
Zuardi, A. W., Crippa, J. A. S., Hallak, J. E. C., Pinto, J. P., Chagas, M. H. N., Rodrigues, G. G. R., .Dursun, S. M., & Tumas, V. (2009). Cannabidiol for the treatment of psychosis in Parkinson’s disease. Journal of Psychopharmacology, 23(8), 979-983.
Keywords: cbd dosage cbd effects medical benefits of cbd cbd for seizures cbd for anxiety cbd for pain cbd products does cbd interact with other medications does cbd interacts with medications cbd interactsions with other drugs what drugs can be taken with cbd antidepressants statins beta-blockers vyvanse ibuprofen adderall benadryl baclofen trazodone predinizone